Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
about
Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain.Direct inhibitory effects of pioglitazone on hepatic fetuin-A expressionThe effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patientsManagement of the metabolic effects of HIV and HIV drugs.Radiation-induced cognitive impairment--from bench to bedsideEfficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population.Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.Carotid intima-media thickness and the prediction of vascular events.Radiation-induced brain injury: A reviewDo thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting.Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic ImplicationsMolecular, Cellular and Functional Effects of Radiation-Induced Brain Injury: A ReviewEffects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies.A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.Plausible anti-inflammatory mechanism of resveratrol and caffeic acid against chronic stress-induced insulin resistance in mice.Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice.Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
P2860
Q35073600-B4E7275E-37B6-486A-BFCC-170CAC589B37Q35097489-9E0A39DB-850C-45E2-8A48-32A3CFC566B0Q35528786-49E87514-DF05-42AC-91E7-2E14D495692AQ36021411-D97BB417-C955-45E4-8DD1-2E133A3BA5C3Q36344693-49BE4FF9-31D2-47A5-B013-43DF4C2A5C1AQ36362830-9CAD6E27-8BC7-4F94-A1C7-8E728EC445B5Q37169533-5D3325C1-B205-448D-B397-39765198D301Q37238946-F8BF8D6A-E409-4C9B-9D6D-414B64147567Q37577159-4ED874B8-FE13-4E5B-9DC9-48759F72A4B3Q38018563-F0932B33-C617-4698-88C0-5D35FD8E5CBDQ38029608-6B08D1EE-0B82-4E09-96E8-DF0D6E791F23Q38092275-708A7B1F-7775-4A35-AB09-6055CE58E04FQ38155997-4D2EEE53-B362-498D-9484-AE3D1F7CA017Q38546589-145029EC-5E99-4165-A6CD-7DE0C42AE8A4Q38648782-821A2C0C-1A07-418A-B536-D893353F7988Q39779416-507F1ECF-F87F-4C94-9F0F-C41DF2CFBDE1Q43612314-53240FEA-EB9A-49EE-BCA3-35A109747E28Q45218410-F698C2A3-355D-45F0-BC74-6A963834676AQ48038700-E054D78F-E830-41C0-8266-B22A0627E6AAQ48160690-FC6F2502-B65F-47E0-A319-656B7152ADA0Q48497036-4C49BE5B-F0F2-43B2-8D23-69A19F8F83C5Q48614072-113CB56A-19F7-4FC5-ACC0-038108E64B1AQ51349530-2C5CBD22-66CF-4F06-BCA5-61E1945FF4D7Q51365744-9E3077C7-C6A5-4A3F-BE93-AB8161BAAF38
P2860
Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and tolerability of p ...... ral antihyperglycaemic agents.
@en
Efficacy and tolerability of p ...... ral antihyperglycaemic agents.
@nl
type
label
Efficacy and tolerability of p ...... ral antihyperglycaemic agents.
@en
Efficacy and tolerability of p ...... ral antihyperglycaemic agents.
@nl
prefLabel
Efficacy and tolerability of p ...... ral antihyperglycaemic agents.
@en
Efficacy and tolerability of p ...... ral antihyperglycaemic agents.
@nl
P2860
P1433
P1476
Efficacy and tolerability of p ...... oral antihyperglycaemic agents
@en
P2093
Giuseppe Derosa
P2860
P304
P356
10.2165/11538100-000000000-00000
P577
2010-10-01T00:00:00Z
P6179
1007297354